Palisade Bio (PALI) Common Equity (2010 - 2026)
Palisade Bio (PALI) posted quarterly Common Equity of $127.4 million for Q1 2026, up 2289.08% year-over-year from $5.3 million in Q1 2025, and down 1.56% quarter-over-quarter from $129.4 million in Q4 2025.
Palisade Bio (PALI) Common Equity (2010 - 2026) Analysis & Trends
Palisade Bio (PALI) has reported Common Equity for 17 consecutive years, with $127.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity rose 2289.08% year-over-year to $127.4 million; the TTM figure through Mar 2026 stood at $127.4 million (up 2289.08% YoY), while the FY2025 annual figure was $129.4 million, up 1626.91% from the prior year.
- Common Equity slipped to $127.4 million in Q1 2026 per PALI's latest filing, from $129.4 million in the prior quarter.
- Across five years, Common Equity topped out at $129.4 million in Q4 2025 and bottomed at $2.6 million in Q2 2025.
- Historically, Common Equity has averaged $23.0 million across 5 years, with a median of $10.1 million in 2024.
- Annual changes were most pronounced in 2025 — Common Equity slumped 73.67% — and 2026, when it jumped 2289.08%.
- Palisade Bio's Common Equity stood at $12.5 million in 2022, then declined by 9.34% to $11.3 million in 2023, then sank by 33.78% to $7.5 million in 2024, then soared by 1626.91% to $129.4 million in 2025, then decreased by 1.56% to $127.4 million in 2026.
- Business Quant data shows PALI's Common Equity at $127.4 million in Q1 2026, $129.4 million in Q4 2025, and $3.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Palisade Bio | 372.94 Mn | 247.74 Mn | - | 121.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 121.75 Mn |
| Mar 31, 2026 | 127.36 Mn |
| Dec 31, 2025 | 129.38 Mn |
| Sep 30, 2025 | 3.21 Mn |
| Jun 30, 2025 | 2.62 Mn |
| Mar 31, 2025 | 5.33 Mn |
| Dec 31, 2024 | 7.49 Mn |
| Sep 30, 2024 | 6.61 Mn |
| Jun 30, 2024 | 9.95 Mn |
| Mar 31, 2024 | 10.06 Mn |
| Dec 31, 2023 | 11.31 Mn |
| Sep 30, 2023 | 14.08 Mn |
| Jun 30, 2023 | 15.80 Mn |
| Mar 31, 2023 | 13.75 Mn |
| Dec 31, 2022 | 12.48 Mn |
| Sep 30, 2022 | 12.43 Mn |
| Jun 30, 2022 | 4.21 Mn |
| Mar 31, 2022 | 4.79 Mn |
| Dec 31, 2021 | 7.37 Mn |
| Sep 30, 2021 | 3.92 Mn |